Key result
Advancing ischemic heart failure linked to increased cardiomyocyte but decreased non-cardiomyocyte ACE2 expression.
Why the study?
Does the expression of ACE2 protein in cardiomyocytes and non-cardiomyocytes change across different stages of ischemic heart failure?
Cross-Sectional (n=103)
Blinded observer for image analysis
No
Does the expression of ACE2 protein in cardiomyocytes and non-cardiomyocytes change across different stages of ischemic heart failure?
The shift in ACE2 protein expression—increasing in cardiomyocytes and decreasing in non-cardiomyocytes—correlates with left ventricular mass, suggesting a significant role in cardiac remodeling during ischemic heart failure progression.
Cell-specific ACE2 shifts in ischemic HF should not change practice; hypothesis-generating for remodeling roles.
The angiotensin-converting enzyme 2 (ACE2)-angiotensin-(1-7)-Mas receptor axis plays a significant role in regulating myocardial remodeling and the development of heart failure (HF), with ACE2 being the primary focus. However, contemporary understanding of the membrane-bound form of the human ACE2 protein remains insufficient. The purpose of this study was to determine the expression of ACE2 protein in different cells of the left ventricular myocardium in non-diseased hearts and at various stages of ischemic HF. A total of 103 myocardial tissue samples from the left ventricle underwent quantitative and semi-quantitative immunohistochemical analysis. Upon assessing ACE2 immunostaining in all myocardial cells through unselective digital image analysis, there was no change in the stage A HF group. Nevertheless, the expression of ACE2 membrane protein in cardiomyocytes showed a tendency to increase, while non-cardiomyocyte ACE2 expression decreased significantly (p < 0.001). In the stage B HF group, the intensity of ACE2 immunostaining continued to increase with rising cardiomyocyte ACE2 expression (p < 0.001). Non-cardiomyocyte expression, in contrast, remained similar to that observed in the stage A HF group. In the stages C/D HF group, ACE2 expression reached its highest level in cardiomyocytes (p < 0.001), while ACE2 expression in non-cardiomyocytes was the lowest (p < 0.001). These changes in ACE2 protein levels are associated with left ventricular remodeling in ischemic HF.
No takes yet. Share an insight, caveat, or question.
Siratavičiūtė et al. (2023) conducted a cross-sectional in Ischemic Heart Failure (n=103). Ischemic heart failure progression (Stages A, B, C/D) vs. Non-diseased hearts (control group) was evaluated on Expression of ACE2 protein in different cells of the left ventricular myocardium (p=<0.001). With advancing stages of ischemic heart failure, ACE2 membrane protein expression significantly increased in cardiomyocytes (p < 0.001) but significantly decreased in non-cardiomyocytes (p < 0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: